Novel anti-muscarinic agents, such as solifenacin, have greater selectivity for bladder receptors than older drugs, and this is reflected in better clinical tolerability. In clinical trials, solifenacin of 5 mg and 10 mg once daily has been shown to reduce micturitions/24 h, urgency/24 h, episodes of urge incontinence and nocturia and to increase the volume of urine voided per micturition. Solifenacin was also well tolerated, with a similar incidence of side effects to placebo. Only dry mouth, constipation and blurred vision were slightly more common with solifenacin than with placebo. Further experience on the safety and efficacy of solifenacin is being obtained during long-term, 12-month follow-up.